BCRX vs KYMR vs PRAX vs IQV

For growth investors, BioCryst Pharmaceuticals, Inc.

(BCRX) is the stronger pick with 94. 1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). BioCryst Pharmaceuticals, Inc. (BCRX) offers the better valuation at 7. 4x trailing P/E, making it the more compelling value choice. Analysts rate BioCryst Pharmaceuticals, Inc. (BCRX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, BioCryst Pharmaceuticals, Inc.

(BCRX) is the cheapest at 7. 4x versus IQVIA Holdings Inc. at 22. 8x.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to -32. 2% for BioCryst Pharmaceuticals, Inc. (BCRX). Over 10 years, the gap is even starker: BCRX returned +181. 7% versus PRAX's -20. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioCryst Pharmaceuticals, Inc.

(BCRX) is the lower-risk stock at 0. 83β versus Praxis Precision Medicines, Inc. 's 1. 40β — meaning PRAX is approximately 69% more volatile than BCRX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioCryst Pharmaceuticals, Inc.

(BCRX) is pulling ahead at 94. 1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: BioCryst Pharmaceuticals, Inc. grew EPS 381. 4% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, BCRX leads at 47. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioCryst Pharmaceuticals, Inc.

(BCRX) is the more profitable company, earning 30. 2% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 30. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCRX leads at 39. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BCRX: 89.

4% to $16. 86.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioCryst Pharmaceuticals, Inc.

(BCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83), +181. 7% 10Y return). Both have compounded well over 10 years (BCRX: +181. 7%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BCRX is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.